Cited 4 times in
At least one cyclic teriparatide administration can be helpful to delay initial onset of a new osteoporotic vertebral compression fracture
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김학선 | - |
dc.contributor.author | 문성환 | - |
dc.contributor.author | 박진오 | - |
dc.contributor.author | 석경수 | - |
dc.contributor.author | 이환모 | - |
dc.date.accessioned | 2015-12-28T10:57:04Z | - |
dc.date.available | 2015-12-28T10:57:04Z | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 0513-5796 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/138374 | - |
dc.description.abstract | PURPOSE: Teriparatide markedly increases bone formation and strength, while reducing the incidence of new-onset osteoporotic vertebral compression fractures (OVCFs). In some countries, expenses for teriparatide use are covered by medical insurance for up to 6 months; however, the national medical insurance of the authors' country does not cover these expenses. This retrospective cohort study compared the therapeutic effects of teriparatide on the initial onset of a new OVCF after treatment of osteoporosis and/or related OVCFs with regard to therapeutic durations of longer than 3 months (LT3M) or shorter than 3 months (ST3M). MATERIALS AND METHODS: From May 2007 to February 2012, 404 patients who were prescribed and administered teriparatide and who could be followed-up for longer than 12 months were enrolled. They were divided into two groups depending on teriparatide duration: LT3M (n=132) and ST3M (n=272). RESULTS: The group with the teriparatide duration of LT3M showed significantly less development of an initial OVCF within 1 year (p=0.004, chi-square). Duration of teriparatide use, body mass index, pre-teriparatide lowest spinal bone mineral density, and severity of osteoporosis significantly affected multiple regression analysis results (p<0.05). Survival analysis of first new-onset OVCFs demonstrated a significantly better survival rate for the LT3M group (log rank, p=0.005). Also, the ST3M group showed a higher odds ratio of 54.00 for development of an initial OVCF during follow-up than the LT3M group (Mantel-Haenzel common odds ratio, p=0.006). CONCLUSION: At least one cyclic teriparatide administration is recommended to provide a protective effect against the initial onset of a new OVCF for up to one year after therapy. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 1576~1583 | - |
dc.relation.isPartOf | YONSEI MEDICAL JOURNAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Bone Density/drug effects | - |
dc.subject.MESH | Bone Density Conservation Agents/administration & dosage* | - |
dc.subject.MESH | Bone Density Conservation Agents/pharmacology | - |
dc.subject.MESH | Cohort Studies | - |
dc.subject.MESH | Drug Administration Schedule | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fractures, Compression/drug therapy* | - |
dc.subject.MESH | Fractures, Compression/etiology | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Incidence | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Osteoporosis/complications | - |
dc.subject.MESH | Osteoporotic Fractures/drug therapy* | - |
dc.subject.MESH | Osteoporotic Fractures/etiology | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Spinal Fractures/drug therapy* | - |
dc.subject.MESH | Spinal Fractures/etiology | - |
dc.subject.MESH | Teriparatide/administration & dosage* | - |
dc.subject.MESH | Teriparatide/pharmacology | - |
dc.subject.MESH | Time Factors | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | At least one cyclic teriparatide administration can be helpful to delay initial onset of a new osteoporotic vertebral compression fracture | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Orthopedic Surgery (정형외과학) | - |
dc.contributor.googleauthor | Kyung Soo Suk | - |
dc.contributor.googleauthor | Hwan Mo Lee | - |
dc.contributor.googleauthor | Seong Hwan Moon | - |
dc.contributor.googleauthor | Hee June Kim | - |
dc.contributor.googleauthor | Hak Sun Kim | - |
dc.contributor.googleauthor | Jin Oh Park | - |
dc.contributor.googleauthor | Byung Ho Lee | - |
dc.identifier.doi | 10.3349/ymj.2014.55.6.1576 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01093 | - |
dc.contributor.localId | A01365 | - |
dc.contributor.localId | A01703 | - |
dc.contributor.localId | A01926 | - |
dc.contributor.localId | A03333 | - |
dc.relation.journalcode | J02813 | - |
dc.identifier.eissn | 1976-2437 | - |
dc.identifier.pmid | 25323894 | - |
dc.subject.keyword | Osteoporosis | - |
dc.subject.keyword | duration | - |
dc.subject.keyword | teriparatide | - |
dc.subject.keyword | vertebral compression fracture | - |
dc.contributor.alternativeName | Kim, Hak Sun | - |
dc.contributor.alternativeName | Moon, Seong Hwan | - |
dc.contributor.alternativeName | Park, Jin Oh | - |
dc.contributor.alternativeName | Suk, Kyung Soo | - |
dc.contributor.alternativeName | Lee, Hwan Mo | - |
dc.contributor.affiliatedAuthor | Kim, Hak Sun | - |
dc.contributor.affiliatedAuthor | Moon, Seong Hwan | - |
dc.contributor.affiliatedAuthor | Park, Jin Oh | - |
dc.contributor.affiliatedAuthor | Suk, Kyung Soo | - |
dc.contributor.affiliatedAuthor | Lee, Hwan Mo | - |
dc.citation.volume | 55 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 1576 | - |
dc.citation.endPage | 1583 | - |
dc.identifier.bibliographicCitation | YONSEI MEDICAL JOURNAL, Vol.55(6) : 1576-1583, 2014 | - |
dc.identifier.rimsid | 49133 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.